COPD Phenotypes: The Future of COPD

Abstract: Significant heterogeneity of clinical presentation and disease progression exists within COPD. While FEV 1 inadequately describes this heterogeneity, a clear alternative has not emerged. The goal of phenotyping is to identify patient groups with unique prognostic or therapeutic characteristics, but significant variation and confusion surrounds use of the term “phenotype” in COPD. “Phenotype” classically refers to any observable characteristic of an organism, and up until now, multiple disease characteristics have been termed COPD “phenotypes”. We, however, propose the following variation on this definition: “a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes (symptoms, exacerbations, response to therapy, rate of disease progression or death).” This more focused definition allows for classification of patients into distinct prognostic and therapeutic subgroups for both clinical and research purposes. Ideally, individuals sharing a unique phenotype would also ultimately be determined to have a similar underlying biologic or physiologic mechanism(s) to guide the development of therapy where possible. It follows that any proposed phenotype whether defined by symptoms, radiography, physiology, cellular or molecular fingerprint will require an iterative, validation process in which “candidate” phenotypes are identified before their relevance to clinical outcome is determined. While this schema represents an ideal construct, we acknowledge any phenotype may be etiologically heterogeneous and that any one individual may manifest multiple phenotypes. We have much yet to learn, but establishing a common language for future research will facilitate our understanding and management of the complexity implicit to this disease. Key words: prognosis, mortality, decline, therapy, outcomes